Our study provides the first evidence that the NFKB1 rs230510 and CCL2rs4586 are significantly associated with the clinical outcome in patients with locoregional gastric cancer.
IFN-γ and IL-10 levels were significantly higher in early (I/II) and late stage (III/IV) gastric cancer; IL-1β and IL-8 were higher and MCP-1 was lower only in late stage (IV) patients.
A specific phosphoinositide 3-kinase (PI3K) inhibitor, wortmannin, was used to test the effect of PI3K inhibition on the secretion of CCL-2 in gastric cancer.
Our data suggest that the genetic polymorphism CCL2A-2518G may not only be associated with an increased risk of gastric cancer, but also with advanced stage of gastric cancer in the Chinese population.